Patients with breast cancer who have government insurance face a higher risk of death, according to a retrospective study presented at the 2019 San Antonio Breast Cancer Symposium on December 13.
Patients with breast cancer who have government insurance face a higher risk of death, according to a retrospective study presented at the 2019 San Antonio Breast Cancer Symposium on December 13.
The study, conducted by researchers in the ECOG-ACRIN Cancer Research Group, looked at 9800 women diagnosed with breast cancer who participated in randomized clinical trials. Patients enrolled in 2 separate chemotherapy treatment trials between 1999 and 2002 (study E1199) and between 2007 and 2011 (study E5103) were included.
“Having insurance in and of itself was not enough to ensure access to a clinical trial or a good clinical outcome,” said Samilia Obeng-Gyasi, MD, the lead researcher of the study.
Each patient’s neighborhood socioeconomic status was also evaluated. Researchers linked zip codes to county-level data on occupation, income, poverty wealth, education, and crowding. However, the study found this status was not associated with trial completion or survival.
Overall, patients with Medicare and Medicaid were “much less likely to participate in a clinical trial compared to their privately insured counterparts.” The women covered by the government who did participate in the trials were more likely to stop their treatment earlier and had lower survival rates.
The majority of women included in the studies had private insurance, while only about 13% of the patients received government insurance. According to researchers, 1 out of every 4 patients with government coverage in E1199 did not complete treatment, compared with 1 out of every 7 privately insured women. In the second study, E5103, “approximately 1 out of every 2 government insured patients did not complete therapy compared to 1 out of every 3 privately insured patients.”
In addition, in E1199 the risk of death of government insured patients increased by one-half while in E5103 that risk increased by one-third.
“With continued changes to insurance at the federal and state levels, physicians and policy makers would benefit from having more data such as what we produced in our study,” said Obeng-Gyasi, highlighting the importance of the research.
Obeng-Gyasi studies social determinants of cancer care as a breast surgical oncologist at The Ohio State University.
“Right now, most clinical trials do not collect data on social determinants of health. If they did, the information could lead us to better understand the interaction of insurance status and many other factors on the clinical outcomes of clinical trial participants,” she said.
Reference
Obeng-Gyasi S, O’Neil A, Zhao F, et al; ECOG-ACRIN Cancer Research Group. Breast cancer patients with government insurance at higher risk of death. Presented at: San Antonio Breast Cancer Symposium; December 13, 2019; San Antonio, TX. Abstract PD10-09.
Navigating Health Policy in an Election Year: Insights From Dr Dennis Scanlon
April 2nd 2024On this episode of Managed Care Cast, we're talking with Dennis Scanlon, PhD, the editor in chief of The American Journal of Accountable Care®, about prior authorization, price transparency, the impact of health policy on the upcoming election, and more.
Listen
Prices for care at hospital trauma centers vary across hospitals; drug shortages reached a record high during the first quarter of 2024; although 3 of the biggest makers of asthma inhalers pledged to cap out-of-pocket costs for some US patients at $35, these do not apply to daily inhalers used by the youngest kids with asthma.
Read More
Exploring Medicare Advantage Prior Authorization Variations
March 26th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the March 2024 issue of The American Journal of Managed Care® about their findings on variations in prior authorization use across Medicare Advantage plans.
Listen
The Biden administration recently launched the Global Health Security Strategy, a new effort to combat the spread of infectious diseases; lawmakers zeroed in on the risks of massive consolidation in health care during the first congressional hearing on the Change Healthcare hack; the FDA recently announced the recall of a pair of heart devices linked to numerous deaths and injuries.
Read More